Boehringer Ingelheim and Eli Lilly and Co. are expanding their clinical trial program for the diabetes drug Jardiance by evaluating the drug”™s effect on exercise ability and heart failure symptoms in people with chronic heart failure.
This new endeavor consists of two Phase III randomized, double-blind trials that evaluate the effect of 12 weeks of treatment with a once-daily dosage of Jardiance 10 mg versus a placebo on exercise ability and heart failure symptoms in patients with chronic heart failure with preserved or reduced ejection fraction. The tests will be measured by the 6-minute walking exercise.
“Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can improve patient health outcomes and fill treatment gaps to serve as a broad cardiometabolic treatment option,” said Thomas Seck, vice president of clinical development and medical affairs ”“ primary care, at the Ridgefield-based Boehringer Ingelheim Pharmaceuticals Inc.
